Femasys has developed FemBloc as a first-in-class non-surgical, permanent female contraception solution performed in a medical office setting without anesthesia or implants.
FemBloc consists of a temporary biopolymer that initiates a wound healing response in the fallopian tubes to form a permanent closure with the patient’s own scar tissue. The biopolymer completely exits the uterine cavity and fallopian tubes naturally over time.
A positive safety profile was demonstrated in the BLOC pilot study (n=49) with no reported serious or unanticipated adverse events.
FemBloc is designed to reduce cost to women and the healthcare system at large. FemBloc may offer an important alternative for those considering surgery or those who rely on other methods of birth control.
The current open-label, multi-center landmark BLOC pivotal trial will establish efficacy and safety.
1 Jones J., et al. Current contraceptive use in the United states, 2006-2010, and changes in patterns of use since 1995: National health statistics reports: no 60. Oct 2012
Femasys has expanded options for women with its commercially available product for diagnosis of infertility (FemVue® Saline-Air Device).
FemVue creates a natural saline and air (bubbles) contrast that is easy to detect with ultrasound to allow for evaluation of the fallopian tubes in a gynecologist’s office.
Safe alternative to existing x-ray procedure eliminating radiation exposure and allergy risk to contrast x-ray dye.
Allows for use of existing ultrasound equipment and eliminates patient referral to radiology.
Immediate results in the convenience of the patient’s own gynecologist’s office.
2 Volpi, E. et al. (1996). Transvaginal sonographic tubal patency testing. UOG,7(1), 43-48. doi:10.1046/j.1469-0705.1996.07010043.x
Femasys Inc. is a privately held corporation committed to transforming women's healthcare worldwide by expanding options
for women with innovative medical devices and next generation advancements providing significant clinical impact.
Our products have been organically conceived, researched and developed by the Company and all manufacturing activities are conducted to ensure compliance with the
U.S. Food and Drug Administration (FDA) per the requirements of 21 CFR 820, as well as ISO 13485.
Femasys has achieved significant milestones to date, including numerous issued patents and filings, clearance of multiple regulatory filings by the U.S. FDA, European Union,
Canada, and Japan with other select countries in process.
Femasys Announces First 100 Women Treated in Pivotal Clinical Trial with FemBloc® Permanent Contraceptive System
ATLANTA, GA, January 04, 2019 – Femasys Inc., a medical technology company developing a platform of innovative in-office solutions for women’s healthcare today announced that the first 100 women in the BLOC pivotal clinical trial received the FemBloc® permanent contraceptive treatment.
Femasys to Participate in Upcoming Investor Conferences
ATLANTA, GA, November 08, 2018 (GLOBE NEWSWIRE) - Femasys Inc., a developer of innovative medical solutions that improve women’s healthcare, today announced that Kathy Lee-Sepsick, Chief Executive Officer and President, will be participating in two upcoming investor conferences.
Femasys Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
ATLANTA, GA, January 4, 2018 -Femasys Inc., a developer of innovative medical solutions for the women's healthcare market, today announced that its Chief Executive Officer and President, Kathy Lee-Sepsick, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 2:30 p.m. PST at the Westin St. Francis Hotel, in San Francisco, CA.
Femasys Appoints Fred Aslan and Charles Larsen to its Board of Directors
Atlanta, GA, March 22, 2016 Femasys Inc., a developer of innovative medical devices for the women's healthcare market today announced that Fred Aslan, Founder and Chief Executive Officer of Advance Medical, Inc. and Vice President of Venrock and Charles E. Larsen, Managing Director of Accuitive Medical Ventures, have been appointed to the Femasys Board of Directors. Both new directors bring significant leadership, operations and commercial experience to Femasys as the Company prepares to commence its pivotal trial of FemBloc™ which is designed to provide women with the first non-surgical permanent contraception option delivered exclusively in the office.
Femasys Announces Todd Creech as Chief Financial Officer
ATLANTA, GA, December 14, 2015 - Femasys Inc., a developer of innovative medical devices for the women's healthcare market today announced the appointment of Todd A. Creech as Chief Financial Officer. Mr. Creech will serve as Femasys' principal financial and accounting officer, will report to Kathy Lee-Sepsick, President and CEO, and will be responsible for all financing, accounting, corporate development and investor activities.
Femasys Secures Term Loan Facility from Silicon Valley Bank
ATLANTA, GA, July 9, 2015 - Femasys Inc., a developer of innovative medical devices for the women's healthcare market, announced today that it has secured a term loan facility from Silicon Valley Bank. Under the loan facility, the company received initial funding and a conditional option to receive additional funding. The Company will use the funds for working capital as it supports the advancement of its groundbreaking non-surgical female sterilization device.
Femasys Announces $40 Million in Series C Financing to Complete Development of FemBloc™
Funding to support pivotal testing of non-surgical permanent contraception solution FemBloc™ -
- IDE approval granted by FDA for U.S. clinical trial of FemBloc; study to start early 2017 -
ATLANTA, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market, today announced that it has closed $40 million in Series C financing. The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor. The Series C syndicate included multiple institutional investors, family offices and a multibillion-dollar global medical device company. The funding will be used primarily to support the pivotal testing of FemBloc™, the Company's revolutionary, non-surgical permanent contraception solution. Femasys designed FemBloc to provide women with the first non-surgical permanent contraceptive option delivered exclusively in the physician's office.